Bangavax
Bangavax (Bancovid) is a COVID-19 vaccine candidate developed by a Bangladeshi pharmaceutical company Globe Biotech Limited.[1][2][3][4][5][6] The vaccine was initially called Bancovid.[7] As of May 2021, Globe Biotech is awaiting for approval to conduct the first clinical trial.
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | mRNA |
Clinical data | |
Other names | Bancovid |
Routes of administration | Intramuscular |
ATC code |
|
HistoryEdit
On 2 July 2020, Globe Biotech Limited anounced to be the first company from Bangladesh to have a Covid-19 vaccine under development.[1] The lone Bangladeshi company actually developed three COVID-19 vaccine candidates with different technologies.[8] The company named the mRNA based vaccine as Bancovid then renamed to Bangavax.[7] Globe Biotech took all the necessary steps from December 2020 to January 2021 to get the permission for ethical approval to conduct the first clinical trial of Bangavax.[4]
ReferencesEdit
- ^ a b "Globe Biotech's Covid-19 vaccine 'BANCOVID' listed by WHO". Daily Sun. 17 October 2020. Retrieved 28 April 2021.
- ^ "'Bangavax' to get approval within a week". dailyobserver. 25 April 2021. Retrieved 28 April 2021.
- ^ "Globe Biotech applies for clinical trial". Prothom Alo. 17 January 2021. Retrieved 28 April 2021.
- ^ a b "Globe Biotech yet to get BMRC nod for human trials". Dhaka Tribune. 22 February 2021. Retrieved 28 April 2021.
- ^ "Bangladesh joins global COVID-19 vaccine race with Bongavax set for clinical trial". Arab News. 8 January 2021. Retrieved 28 April 2021.
- ^ "BANCOVID, the first D614G variant mRNA-based vaccine candidate against SARS-CoV-2 elicits neutralizing antibody and balanced cellular immune response". bioRxiv. Retrieved 28 April 2021.
- ^ a b "Globe Biotech to produce vaccine candidate for clinical trial". The Financial Express. 6 January 2021. Retrieved 28 April 2021.
- ^ "3 Covid-19 vaccine candidates by Bangladesh's Globe Biotech enlisted in WHO draft landscape". The Daily Star. 17 October 2020. Retrieved 4 May 2021.
Scholia has a profile for Bangavax (). |